Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Monogram Technologies Inc. recently ...

LOS ANGELES, July 29, 2025 (GLOBE NEWSWIRE) -- Altanine, Inc., a pharmaceutical company advancing proprietary drug delivery technologies across high-growth therapeutic areas, today announced the ...

C shares are redeemed or converted and preferred series D reduced 68.5% in outstanding shares BNB coin has appreciated over 17% since Windtree announced crypto treasury agreement with Build and Build ...

Unique Differentiation: The team addressed what sets Fifty 1 AI Labs apart: a focus on off-patent repurposing with real-world data and adaptive trials for faster, affordable therapies, backed by ...

The Adam Ferrari Health Science Scholarship has closed its application window and will announce a recipient from the pool of applicants in August 2025.

A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be ...

BriaPro is a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors ...

The Company continued further restructuring activities during 2025 including severance, employee-related and facility exit costs. Cost of goods sold includes the benefit received from the sale of ...

Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QUANTDx™, a new product line of ...

Molecular breast imaging (“ MBI ”) is an emerging modality that uses gamma radiation and injectable radioactive tracers. It is typically reserved for investigational diagnostic imaging and delivers a ...

For those pushing beyond average gains, the CrazyBulk Growth Hormone Stack is engineered for elite-level performance and ...

Kiniksa is recruiting patients in the dose-focusing portion of the Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis. The company expects data from this portion of the trial in the second ...